{"id":61998,"date":"2025-10-09T16:04:10","date_gmt":"2025-10-09T14:04:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/"},"modified":"2025-10-09T16:04:10","modified_gmt":"2025-10-09T14:04:10","slug":"modus-create-appoints-sharon-lynch-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/","title":{"rendered":"Modus Create Appoints Sharon Lynch as Chief Executive Officer"},"content":{"rendered":"
\n

RESTON, Va.–(BUSINESS WIRE)–Modus Create, a global leader in digital product engineering, today announced the appointment of Sharon Lynch<\/b> as Chief Executive Officer (CEO). Lynch succeeds Pat Sheridan<\/b>, co-founder of Modus Create, who will transition to the role of Chairman.<\/p>\n

<\/a>
<\/a><\/p>\n

\nLynch brings a proven track record of helping organizations innovate, scale, and thrive in rapidly evolving markets. Most recently, she led Slalom\u2019s product engineering organization, Slalom Build, where she led a team of over 1,300 people throughout the Americas.<\/p>\n

\n\u201cI\u2019m honored to join Modus Create at such a pivotal moment in our industry,\u201d said Sharon Lynch, CEO of Modus Create<\/b>. \u201cFrom the moment I began learning about Modus, I was inspired by the talent, global reach, and relentless client focus of this team. Pat and the leadership group have built an incredible foundation, and I look forward to leading Modus into its next chapter. One where we help our clients modernize, adopt next-generation technologies, and thrive in a rapidly changing digital era.\u201d<\/p>\n

\nOutgoing CEO Pat Sheridan<\/b>, who co-founded Modus Create in 2011, expressed confidence in the transition. \u201cOver the past 14 years, Modus Create has grown into a global company built on innovation, collaboration, and an unwavering commitment to our clients,\u201d said Sheridan. \u201cAs we look ahead to the AI era, I can think of no better leader than Sharon to take the helm. She embodies the core DNA of Modus: experienced, visionary, and deeply aligned with our values. I\u2019m confident she will honor our culture while leading us into an exciting future.\u201d<\/p>\n

\nLynch brings more than 25 years of leadership experience in technology consulting and product engineering, and is passionate about uniting diverse perspectives to solve complex problems and fostering cultures where collaboration and innovation thrive. Known for leading with clarity, curiosity, and conviction, Lynch will focus on accelerating Modus Create\u2019s growth by aligning with client needs, scaling innovative services, and empowering its global talent network to deliver lasting impact.<\/p>\n

\nBacked by JLL Partners, a leading private equity firm, Modus Create is entering its next phase of growth and global expansion.<\/p>\n

\n\u201cSharon\u2019s addition marks an exciting new chapter for Modus Create,” said Gerard Van Spaendonck, Head of Value Creation at JLL Partners. “Her track record of scaling technology firms makes her exceptionally well-suited to guide Modus Create in this next stage. We look forward to supporting her as she executes the company’s strategy and expands its global presence.”<\/p>\n

\nModus Create sits at the intersection of technology and business impact, helping organizations streamline operations through differentiated digital engineering. For 14 years, the company has delivered measurable results across industries.<\/p>\n

\nIn the healthcare and pharmaceutical sectors, Modus Create has helped companies accelerate clinical trial protocol reviews, modernize data platforms, automate review processes, and build out entire direct-to-patient health platforms, all while maintaining strict regulatory standards.<\/p>\n

\nModus Create has also worked with firms across the financial services and consumer sectors, helping to build and maintain the cloud infrastructure platform for a new credit card launch, and creating a visualization tool that boosted buyer engagement and digital purchases for a leading automaker.<\/p>\n

\nAbout Modus Create<\/b><\/p>\n

\nModus Create is a digital product engineering partner for forward-thinking businesses. Our global teams work side-by-side with clients to design, build, and scale custom solutions that achieve real results and lasting change. Learn more at www.moduscreate.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nDavid Fitzpatrick
\n
VP, Marketing
\n
david.fitzpatrick@moduscreate.com<\/a>
(855) 663-8727<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

RESTON, Va.–(BUSINESS WIRE)–Modus Create, a global leader in digital product engineering, today announced the appointment of Sharon Lynch as Chief Executive Officer (CEO). Lynch succeeds Pat Sheridan, co-founder of Modus Create, who will transition to the role of Chairman. Lynch brings a proven track record of helping organizations innovate, scale, and thrive in rapidly evolving … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61998","6":"format-standard","7":"category-industry"},"yoast_head":"\nModus Create Appoints Sharon Lynch as Chief Executive Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Modus Create Appoints Sharon Lynch as Chief Executive Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RESTON, Va.–(BUSINESS WIRE)–Modus Create, a global leader in digital product engineering, today announced the appointment of Sharon Lynch as Chief Executive Officer (CEO). Lynch succeeds Pat Sheridan, co-founder of Modus Create, who will transition to the role of Chairman. Lynch brings a proven track record of helping organizations innovate, scale, and thrive in rapidly evolving ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-09T14:04:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251009778437\/en\/2602775\/22\/Modus_vertical_logo_black.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Modus Create Appoints Sharon Lynch as Chief Executive Officer\",\"datePublished\":\"2025-10-09T14:04:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/\"},\"wordCount\":572,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251009778437\\\/en\\\/2602775\\\/22\\\/Modus_vertical_logo_black.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/\",\"name\":\"Modus Create Appoints Sharon Lynch as Chief Executive Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251009778437\\\/en\\\/2602775\\\/22\\\/Modus_vertical_logo_black.jpg\",\"datePublished\":\"2025-10-09T14:04:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251009778437\\\/en\\\/2602775\\\/22\\\/Modus_vertical_logo_black.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251009778437\\\/en\\\/2602775\\\/22\\\/Modus_vertical_logo_black.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Modus Create Appoints Sharon Lynch as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Modus Create Appoints Sharon Lynch as Chief Executive Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"Modus Create Appoints Sharon Lynch as Chief Executive Officer - Pharma Trend","og_description":"RESTON, Va.–(BUSINESS WIRE)–Modus Create, a global leader in digital product engineering, today announced the appointment of Sharon Lynch as Chief Executive Officer (CEO). Lynch succeeds Pat Sheridan, co-founder of Modus Create, who will transition to the role of Chairman. Lynch brings a proven track record of helping organizations innovate, scale, and thrive in rapidly evolving ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-09T14:04:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251009778437\/en\/2602775\/22\/Modus_vertical_logo_black.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Modus Create Appoints Sharon Lynch as Chief Executive Officer","datePublished":"2025-10-09T14:04:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/"},"wordCount":572,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251009778437\/en\/2602775\/22\/Modus_vertical_logo_black.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/","url":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/","name":"Modus Create Appoints Sharon Lynch as Chief Executive Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251009778437\/en\/2602775\/22\/Modus_vertical_logo_black.jpg","datePublished":"2025-10-09T14:04:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251009778437\/en\/2602775\/22\/Modus_vertical_logo_black.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251009778437\/en\/2602775\/22\/Modus_vertical_logo_black.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/modus-create-appoints-sharon-lynch-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Modus Create Appoints Sharon Lynch as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61998"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61998\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}